ASX Release | 9 November 2026

Memphasys secures New Zealand public healthcare agreement for Felix – 1,200 cartridges contracted

Highlights

- **New Zealand public healthcare agreement:** Felix to be supplied to Fertility Plus, a government-operated IVF clinic in Auckland, under a two-year agreement with Health New Zealand | Te Whatu Ora.
- **1,200 Felix cartridges contracted:** Minimum purchase volume specified over the initial two-year term, including 500 cartridges and one console in the initial delivery.
- **Direct Australia–New Zealand commercial strategy:** Expanding the home-market presence while protecting margins and strengthening clinical and customer support.
- **International commercial momentum continues:** Another market added to Felix's expanding footprint across Europe, Australia, Asia and the Middle East, supporting recurring cartridge revenue growth.

Memphasys Limited (ASX: MEM) (Memphasys or the Company) is pleased to announce its first New Zealand commercial agreement for Felix, its sperm preparation technology. The two-year agreement **with Health New Zealand** | Te Whatu Ora will supply Fertility Plus, a government-operated IVF clinic at Auckland's Greenlane Clinical Centre.

The agreement specifies a minimum purchase volume of **1,200 Felix cartridges** over the initial term, beginning with 500 cartridges and one Felix console. It extends the Company's international commercial footprint and supports its strategy of turning commercial opportunities into long-term customer relationships and recurring consumables revenue.

Strengthening the Australia–New Zealand commercial platform

Memphasys is focused on establishing a leading direct-to-clinic presence across its home markets of Australia and New Zealand, maximising market penetration, protecting margins and strengthening customer relationships. This strategy is designed to capture greater commercial value while delivering superior clinical and technical support, complementing the Company's expanding international go-direct commercial/distribution approach and other strategic partnerships.

International commercial momentum

Following commercial agreements across Europe, Australia, Asia and the Middle East, the New Zealand agreement demonstrates the appeal of Felix across diverse markets. The Company remains focused on growing its IVF clinic installed base and converting customer adoption into repeat cartridge purchases.

Memphasys Limited
Level 1, 34-36 Richmond Road
Homebush West, NSW 2140

Contact Details
P +612 8415 7300

E info@memphasys.com
W memphasys.com
ABN 33 120 047 556

Marjan Mikel, Chair of the Memphasys Commercialisation Committee, commented:

"This is another significant milestone in our international expansion. Securing an agreement with Health New Zealand for a publicly operated IVF clinic reinforces the global appeal of Felix and its potential to help more people achieve their dream of starting a family.

"The commitment to purchase 1,200 cartridges provides a strong foundation in New Zealand, where we intend to operate directly alongside Australia to protect margins and deliver excellent customer support. From Europe and the Middle East to Asia, Australia and now New Zealand, the Felix value proposition continues to resonate, strengthening our confidence in growing recurring cartridge revenues."

Material terms of the agreement

The agreement has an initial two-year term commencing 1 November 2026, with a further 24-month renewal period available to Health NZ. It specifies a minimum purchase volume of 1,200 cartridges over the initial term, subject to rollover provisions for any unmet volume. Initial delivery of 500 cartridges and one console is scheduled within 30 days of execution, followed by scheduled quarterly deliveries. Additional orders may be placed.

The agreement is non-exclusive and subject to its contractual termination provisions. Commercial unit pricing is not disclosed.

This announcement has been authorised for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:
Colin Jacoby, Chapter One Advisors
T: +61 439 980 359
E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising Felix, a patented sperm preparation technology for assisted reproduction. Each procedure uses a single-use cartridge, supporting a recurring consumables business model.

Website: www.memphasys.com | The Felix System is a registered trademark of Memphasys Limited. All rights reserved.

Forward Looking Statements

Statements about planned delivery, implementation, clinic adoption, future cartridge demand and commercial opportunities are forward looking and reflect current expectations. They are subject to execution, operational, timing and commercial risks, and actual outcomes may differ materially. Planned deployment, orders, recognised revenue and cash receipts are distinct measures. Memphasys undertakes no obligation to update forward-looking statements except as required by law.